Clinical reference Biomarker Directory
Back to directory

SERPINC1

Established

Antithrombin deficiency is a thrombophilia; its deficiency can also cause resistance to heparin therapy.

Also known as Antithrombin antithrombin III AT
In plain language

Antithrombin naturally slows down blood clotting, and interestingly, the blood thinner heparin only works by teaming up with this same protein. People with low antithrombin can be surprisingly resistant to heparin, sometimes needing higher doses or a completely different blood thinner.

Biomarker & context

SERPINC1 encodes antithrombin, a natural anticoagulant that inhibits thrombin and other clotting factors; its deficiency is one of the classic inherited thrombophilias, and it is also the molecule that heparin depends on to work.

What it indicates

Low antithrombin activity supports hereditary antithrombin deficiency, increasing venous thromboembolism risk; antithrombin can also be acquired-low in liver disease, nephrotic syndrome, or DIC, complicating interpretation in acutely ill patients.

Diagnosis & clinical testing

Measured via functional assay; testing should ideally be done away from acute clotting events, anticoagulant therapy, and conditions causing acquired deficiency, since all of these can produce a falsely low result unrelated to true genetic deficiency.

Guiding treatment

A clinically important interaction: heparin's anticoagulant mechanism depends entirely on binding antithrombin, so patients with antithrombin deficiency can show heparin resistance, requiring higher doses or alternative anticoagulation strategies (like direct thrombin inhibitors) to achieve adequate anticoagulation.

Clinical significance

Heparin's mechanism of action depends on binding antithrombin, making this an important drug-biomarker interaction to recognize.

References
  1. General hematology reference literature on antithrombin deficiency and heparin resistance mechanisms.